Vilastobart in combination with atezolizumab continued to demonstrate a differentiated and generally well-tolerated safety profile. Treatment-related adverse events (AEs) were primarily Grade 1 or 2, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback